Antibiotics and heavy metals have caused serious contamination of the environment and even resulted in public health concerns. It has therefore become even more urgent to adopt a sustainable approach to combating these polluted environments. In this paper, we investigated the microbial community of marine sediment samples after 255 days of enrichment culture under Cu (II) and lincomycin stress and ZC255 was the most resistant strain obtained. The 16S rRNA gene sequence confirmed that it belonged to the genus Rossellomorea. Strain ZC255 was resistant to 12 kinds of antibiotics, and had a superior tolerance to Cu (II), Pb (II), Ni (II), Zn (II), Cr (III), and Cd (II). Moreover, it exhibits strong bioremoval ability of Cu and lincomycin. The removal efficiency of Cu (II) and lincomycin can achieve 651 mg/g biomass and 32.5 mg/g biomass, respectively. Strain ZC255 was a promising isolate for pollution bioremediation applications.

With the widespread use of ionizing radiation (IR) in medical and industrial settings, irradiation has become increasingly common, posing significant risks to human health. Among the various organs affected, the gut is particularly sensitive to radiation-induced damage, leading to conditions such as radiation-induced intestinal damage (RIID). Recent studies have emphasized the critical role of gut microbiota and its metabolites in mitigating radiation-induced injury. This review discusses the effects of IR on the mammalian and human gut microbiota. We examine the dynamics of gut microbiota composition during and after irradiation, and emphasize the protective role of the gut flora and the metabolites in the pathophysiological mechanisms exhibited during radiation injury. In addition, this article investigates how specific metabolites, such as short-chain fatty acids and indole derivatives, may contribute to the mitigation of inflammation and promotion of gut barrier integrity. In addition, various therapeutic strategies based on modulating the gut microbiota, such as probiotics, antibiotics, and fecal microbiota transplantation, are discussed to understand their potential to prevent or mitigate RIID. Understanding the interactions between IR, gut microbiota and their metabolites provides new avenues for developing innovative therapeutic approaches to improve patient outcomes during and after radiotherapy. Future research directions could focus on optimizing microbiota-based therapies and exploring the role of diet and lifestyle in enhancing intestinal health during irradiation.

Heavy metal pollution, particularly copper contamination, threatens the ecological environment and human survival. In response to this pressing environmental issue, the development of innovative remediation strategies has become imperative. Bioremediation technology is characterized by remarkable advantages, including its ecological friendliness, cost-effectiveness, and operational efficiency. In our previous research, Rossellomorea sp. ZC255 demonstrated substantial potential for environmental bioremediation applications. This study investigated the removal characteristics and underlying mechanism of strain ZC255 and revealed that the maximum removal capacity was 253.4 mg/g biomass under the optimal conditions (pH 7.0, 28 °C, and 2% inoculum). The assessment of the biosorption process followed pseudo-second-order kinetics, while the adsorption isotherm may fit well with both the Langmuir and Freundlich models. Cell surface alterations on the Cu(II)-treated biomass were observed through scanning electron microscopy (SEM). Cu(II) binding functional groups were determined via Fourier transform infrared spectroscopy (FTIR) analysis. Simultaneously, the genomic analysis of strain ZC255 identified multiple genes potentially involved in heavy metal resistance, transport, and metabolic processes. These studies highlight the significance of strain ZC255 in the context of environmental heavy metal bioremediation research and provide a basis for using strain ZC255 as a copper removal biosorbent.

Helicobacter pylori (H. pylori) is the primary etiological agent for chronic gastritis, peptic ulcers, and gastric adenocarcinoma. The alarming rise in multidrug-resistant (MDR) strains, particularly against clarithromycin (CLR), metronidazole (MNZ), and levofloxacin (LVX), has severely compromised standard therapies. Thus, there is an urgent clinical need for novel antimicrobial agents that operate through distinct mechanisms to bypass resistance pathways and mitigate gastric cancer risk. We designed and synthesized a series of antimicrobial peptides, focusing on the proteolytically stable all-D-amino acid enantiomer, DT7-3, derived from a probiotic-sourced template. Minimum inhibitory concentrations (MICs) were determined against standard strains and 11 clinical MDR isolates via the broth microdilution method. Antimicrobial mechanisms were elucidated using scanning electron microscopy (SEM) for morphology, fluorescence-based assays for anti-adhesion activity, and real-time qPCR to quantify virulence gene expression (babA, ureA, and vacA). Biocompatibility was assessed using defibrinated sheep erythrocytes, gastric epithelial cells (GES-1), and representative beneficial gut microbiota. Analysis of the clinical isolates revealed resistance rates of 63.6% for CLR/LVX and 81.8% for MNZ, with 54.5% identified as MDR. DT7-3 exhibited superior potency (MIC 1–32 µg/mL) against all strains, significantly outperforming its L-enantiomer counterparts. Mechanistic studies unveiled a “triple-hit” mechanism: (1) rapid membrane disruption; (2) potent inhibition of bacterial adhesion to host cells (~60% reduction at 0.5 × MIC); (3) significant downregulation of critical virulence factors (babA, ureA, and vacA). Furthermore, DT7-3 showed an excellent safety profile, with negligible hemolysis ( 32 relative to mammalian cells. Crucially, DT7-3 showed high selectivity for the pathogen over beneficial gut microbiota (MIC > 128 µg/mL, SI > 16). Crucially, DT7-3 maintained potent bactericidal activity (MIC ≤ 16 µg/mL) even under cholesterol-enriched conditions. The engineered D-peptide DT7-3 is a potent candidate for combating MDR H. pylori. Its multifaceted mechanism, targeting bacterial viability while suppressing core virulence factors, positions it as a robust lead compound for next-generation eradication therapies aimed at reducing the burden of H. pylori-associated diseases.

Radiation-induced intestinal injury (RIII) is a common complication of tumor radiotherapy, significantly impacting patients’ quality of life and posing challenges for developing effective medical countermeasures. This study investigated the reparative effects of the traditional Chinese medicine Pyrrosia petiolosa (Christ) Ching on radiation damage through in vivo and in vitro models. By integrating gut microbiota and untargeted metabolomics analyses, it elucidated the multidimensional mechanisms through which P. petiolosa regulates the microbiome as well as metabolic homeostasis. In vitro experiments demonstrated that P. petiolosa effectively suppressed radiation-induced inflammatory factors (IL-6, TNF-α, and IL-1β) and alleviated radiation-induced oxidative stress (MDA, GSH, and SOD). In vivo models further confirmed that P. petiolosa significantly alleviated radiation-induced intestinal inflammation and leukopenia, while protecting the structural and functional integrity of mouse small intestinal crypt villi. Mechanistic studies revealed P. petiolosa reshaped the gut microbiota by promoting enrichment of beneficial bacteria such as Bacteroides, concurrently restoring the homeostasis of key metabolic pathways, including glutathione, glycerophospholipids, and the tricarboxylic acid cycle. Analysis of the microbiome–metabolome interaction network revealed that treatment with P. petiolosa altered the correlation patterns between gut microbiota and fecal metabolites, including potentially beneficial bacteria and metabolites associated with inflammatory and oxidative stress responses. These findings suggest that microbiome–metabolome remodeling may contribute to the protective effects of P. petiolosa against radiation-induced intestinal damage. Overall, this study provides preliminary evidence that P. petiolosa may alleviate acute radiation-induced intestinal damage through anti-inflammatory and antioxidant effects accompanied by changes in gut microbiota and metabolic homeostasis, while identifying candidate targets for future functional validation.